Drug Repositioning and Target Finding Based on Clinical Evidence.
|アブストラクト||Recent pharmacological studies have been developed based on finding new disease-related genes, accompanied by the production of gene-manipulated disease model animals and high-affinity ligands for the target proteins. However, the emergence of this gene-based strategy in drug development has led to the rapid depletion of drug target molecules. To overcome this, we have attempted to utilize clinical big data to explore a novel and unexpected hypothesis of drug-drug interaction that would lead to drug repositioning. Here, we introduce our data-driven approach in which adverse event self-reports are statistically analyzed and compared in order to find and validate new drug targets. The hypotheses provided by such a data-driven approach will likely impact the style of future drug development and pharmaceutical study.|
|ジャーナル名||Biological & pharmaceutical bulletin|
|投稿者||Kaneko, Shuji; Nagashima, Takuya|
|組織名||Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences,;Kyoto University.|